Bevacizumab对人Tenon囊成纤维细胞转分化的抑制作用
发布时间:2018-10-15 09:29
【摘要】:目的观察Bevacizumab(贝伐单抗)对转化生长因子(transforming growth factor,TGF)-β2诱导下的人Tenon囊成纤维细胞转分化的抑制作用,探讨抗新生血管药物抑制青光眼术后滤过泡瘢痕化的机制。方法用含体积分数10%胎牛血清的DMEM高糖型培养基对人Tenon囊成纤维细胞株进行体外常规培养和传代。实验分为空白对照组、TGF-β2处理组(加入终浓度为10μg·L-1的TGF-β2DMEM完全培养基)及Bevacizumab干预组(加入10μg·L-1的TGF-β2和1.0 g·L-1的Bevacizumab DMEM完全培养基),置于37℃、体积分数5%二氧化碳培养箱中培养48 h,并分别应用细胞免疫荧光染色技术和Western Blot实验检测Bevacizumab对TGF-β2刺激下人Tenon囊成纤维细胞α-平滑肌肌动蛋白(α-smooth muscle actin,α-SMA)表达的影响。结果α-SMA蛋白主要表达在细胞质中,免疫荧光染色结果显示TGF-β2处理组可以见到α-SMA的荧光表达,而Bevacizumab干预组α-SMA蛋白表达受到抑制。Western Blot结果显示空白对照组、TGF-β2处理组及Bevacizumab干预组α-SMA蛋白相对表达量分别为0.630±0.038、1.130±0.071和0.340±0.033,Bevacizumab干预组α-SMA蛋白相对表达量低于空白对照组和TGF-β2处理组(均为P0.05)。结论 Bevacizumab可明显抑制TGF-β2诱导下人Tenon囊成纤维细胞α-SMA蛋白的表达,抑制成纤维细胞表型转化。
[Abstract]:Objective to observe the inhibitory effect of Bevacizumab (bevacizumab) on the transdifferentiation of human Tenon capsule fibroblasts induced by transforming growth factor (transforming growth factor,TGF-尾 2, and to explore the mechanism of anti-angiogenic drugs inhibiting bleb scarring after glaucoma surgery. Methods Human Tenon capsule fibroblasts were cultured and subcultured in vitro on DMEM medium containing 10% fetal bovine serum. The experiment was divided into blank control group, TGF- 尾 2 treatment group (adding 10 渭 g L -1 TGF- 尾 2DMEM complete medium) and Bevacizumab intervention group (10 渭 g L -1 TGF- 尾 2 and 1.0 g L -1 Bevacizumab DMEM complete medium) at 37 鈩,
本文编号:2272105
[Abstract]:Objective to observe the inhibitory effect of Bevacizumab (bevacizumab) on the transdifferentiation of human Tenon capsule fibroblasts induced by transforming growth factor (transforming growth factor,TGF-尾 2, and to explore the mechanism of anti-angiogenic drugs inhibiting bleb scarring after glaucoma surgery. Methods Human Tenon capsule fibroblasts were cultured and subcultured in vitro on DMEM medium containing 10% fetal bovine serum. The experiment was divided into blank control group, TGF- 尾 2 treatment group (adding 10 渭 g L -1 TGF- 尾 2DMEM complete medium) and Bevacizumab intervention group (10 渭 g L -1 TGF- 尾 2 and 1.0 g L -1 Bevacizumab DMEM complete medium) at 37 鈩,
本文编号:2272105
本文链接:https://www.wllwen.com/yixuelunwen/yank/2272105.html
最近更新
教材专著